ViAqua

Categories
Founded

2014

Leadership
  • Shai Ufaz, PhD, Co-Founder and CEO
Headquarters

Haifa, Israel

Website

viaqua-t.com

S2G North Star Interim Outcomes
  • Increased demand for healthier and sustainable seafood Jump to footnote 1
  • Increased uptake of solutions, products, and technologies that enhance productivity of blue economy Jump to footnote 2
ViAqua is a developer of an RNA-particle platform to promote and improve animal health in aquaculture.
ViAqua Therapeutics was established to address the growing need for effective, specific, and affordable health management of diseases in aquaculture. ViAqua is developing a biotechnology-based, oral delivery platform for targeted administration of nucleic acid-based therapeutics. ViAqua’s first product is an RNA-based solution for application against the White Spot Shrimp Virus (WSSV) pandemic.

Insights

News

Footnotes

  1. S2G North Star Interim Outcomes reflect areas of strategic alignment with our long-term impact goals. These outcomes are intended to illustrate the types of non-financial progress S2G seeks to support across its portfolio and do not represent company-specific metrics or outcomes. They are not a reflection of investment performance, actual or realized returns, or future financial results.

  2. S2G North Star Interim Outcomes reflect areas of strategic alignment with our long-term impact goals. These outcomes are intended to illustrate the types of non-financial progress S2G seeks to support across its portfolio and do not represent company-specific metrics or outcomes. They are not a reflection of investment performance, actual or realized returns, or future financial results.